Financials data is unavailable for this security.
View more
Year on year Roche Holding AG 's revenues fell -7.21% from 63.28bn to 58.72bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 12.42bn to 11.50bn, a -7.43% decrease.
| Gross margin | 73.39% |
|---|---|
| Net profit margin | 21.05% |
| Operating margin | 25.82% |
| Return on assets | 13.84% |
|---|---|
| Return on equity | 40.13% |
| Return on investment | 20.84% |
More ▼
Cash flow in CHFView more
In 2023, Roche Holding AG increased its cash reserves by 7.71%, or 385.00m. The company earned 16.10bn from its operations for a Cash Flow Margin of 27.41%. In addition the company used 10.64bn on investing activities and also paid 4.24bn in financing cash flows.
| Cash flow per share | 19.68 |
|---|---|
| Price/Cash flow per share | 11.50 |
| Book value per share | 36.77 |
|---|---|
| Tangible book value per share | 6.39 |
More ▼
Balance sheet in CHFView more
| Current ratio | 1.35 |
|---|---|
| Quick ratio | 1.04 |
| Total debt/total equity | 0.9964 |
|---|---|
| Total debt/total capital | 0.4676 |
More ▼
Growth rates in CHF
Year on year, growth in dividends per share increased 1.05% while earnings per share excluding extraordinary items fell by -6.96%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 3.09% |
|---|---|
| Div growth rate (5 year) | 1.99% |
| Payout ratio (TTM) | 67.57% |
| EPS growth(5 years) | 3.28 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -6.88 |
More ▼
